the aid library

Filter

1270

Direction:

Guidance paper - Assessing country health financing systems: the health financing progress matrix

Jowett, M.; J. Kutzin; S. Kwon et al. World Health Organization (WHO) (2020) CC

This paper outlines the background to and design of the Health Financing Progress Matrix (HFPM), WHO’s standardized qualitative approach to assessing country health financing systems. Primarily qualitative in nature, the HFPM assesses a country’s health financing institutions, processes, policie ... more

Download

View PDF

Global Vaccine Summit 2020 - Chair’s Summary

Global Alliance for Vaccines and Immunisation (Gavi) Global Alliance for Vaccines and Immunisation (Gavi) (2020) CC

The UK government hosted the Global Vaccine Summit on June 4, 2020 under the patronage of the Rt. Hon. Boris Johnson, Prime Minister of the United Kingdom of Great Britain and Northern Ireland. The meeting was held by videoconference in light of the ongoing COVID-19 pandemic. 2. The Summit brought ... more

Download

View PDF

ACT-A - Urgent Priorities & Financing Requirements at 10 November 2020

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2020) CC

Six months after its launch on 24 April, the Access to COVID-19 Tools (ACT) Accelerator has already delivered concrete results in speeding up the development of new therapeutics, diagnostics, and vaccines. Now mid-way through the scale-up phase, the tools we need to fundamentally change the course o ... more

ACT-Accelerator Investment Case

World Health Organization (WHO) World Health Organization (WHO) (2020) CC

This document is intended for countries, foundations, and civil society. It provides a consolidated overview of the Access to COVID-19 Tools (ACT) Accelerator, its goals, and the investments that partners have calculated are required to carry out its mission. Emergency responses are dynamic by natur ... more

Download

View PDF

C20 Eight Proposed Recommendations for Effective G20 Agenda on Finance and Health

Civil Society 20 (C20) - Saudi Arabia 2020 (2020) CC

As a global community of +750 representatives of the world’s civil society, the C20 official Engagement Group of the G20 is submitting a list of policy priorities for the upcoming G20 Finance Ministers & Central Bank Governors meeting on July 18th and the G20 Extraordinary Sherpa Meeting on July 2 ... more

External Link

Estimates of aid for reproductive, maternal, newborn, and child health: findings from application of the Muskoka2 method, 2002–17

Dingle, A.; Schäferhoff, M.; Borghi, J. et al. The Lancet (2020) CC

Background Four methods have previously been used to track aid for reproductive, maternal, newborn, and child health (RMNCH). At a meeting of donors and stakeholders in May, 2018, a single, agreed method was requested to produce accurate, predictable, transparent, and up-to-date estimates that coul ... d be used for analyses from both donor and recipient perspectives. Muskoka2 was developed to meet these needs. We describe Muskoka2 and present estimates of levels and trends in aid for RMNCH in 2002–17, with a focus on the latest estimates for 2017. Methods Muskoka2 is an automated algorithm that generates disaggregated estimates of aid for reproductive health, maternal and newborn health, and child health at the global, donor, and recipient-country levels. We applied Muskoka2 to the Organisation for Economic Co-operation and Development's Creditor Reporting System (CRS) aid activities database to generate estimates of RMNCH disbursements in 2002–17. The percentage of disbursements that benefit RMNCH was determined using CRS purpose codes for all donors except Gavi, the Vaccine Alliance; the UN Population Fund; and UNICEF; for which fixed percentages of aid were considered to benefit RMNCH. We analysed funding by donor for the 20 largest donors, by recipient-country income group, and by recipient for the 16 countries with the greatest RMNCH need, defined as the countries with the worst levels in 2015 on each of seven health indicators. Findings After 3 years of stagnation, reported aid for RMNCH reached $15·9 billion in 2017, the highest amount ever reported. Among donors reporting in both 2016 and 2017, aid increased by 10% ($1·4 billion) to $15·4 billion between 2016 and 2017. Child health received almost half of RMNCH disbursements in 2017 (46%, $7·4 billion), followed by reproductive health (34%, $5·4 billion), and maternal and newborn health (19%, $3·1 billion). The USA ($5·8 billion) and the UK ($1·6 billion) were the largest bilateral donors, disbursing 46% of all RMNCH funding in 2017 (including shares of their core contributions to multilaterals). The Global Fund and Gavi were the largest multilateral donors, disbursing $1·7 billion and $1·5 billion, respectively, for RMNCH from their core budgets. The proportion of aid for RMNCH received by low-income countries increased from 31% in 2002 to 52% in 2017. Nigeria received 7% ($1·1 billion) of all aid for RMNCH in 2017, followed by Ethiopia (6%, $876 million), Kenya (5%, $754 million), and Tanzania (5%, $751 million). Interpretation Muskoka2 retains the speed, transparency, and donor buy-in of the G8's previous Muskoka approach and incorporates eight innovations to improve precision. Although aid for RMNCH increased in 2017, low-income and middle-income countries still experience substantial funding gaps and threats to future funding. Maternal and newborn health receives considerably less funding than reproductive health or child health, which is a persistent issue requiring urgent attention. Funding Bill & Melinda Gates Foundation; Partnership for Maternal, Newborn & Child Health. more

Download

View PDF

Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors

Budreviciute, A.; Damiati, S.; Khdr Sabir, D. et al. (2020) CC

Non-communicable diseases (NCDs) are of increasing concern for society and national governments, as well as globally due to their high mortality rate. The main risk factors of NCDs can be classified into the categories of self-management, genetic factors, environmental factors, factors of medical co ... more

Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment

Mohan, V.; Khunti, K.; Chan,S.P.; et al. National Library of Medicine, National Center for Biotechnology Information (2020) CC3

With the growing prevalence of type 2 diabetes, particularly in emerging countries, its management in the context of available resources should be considered. International guidelines, while comprehensive and scientifically valid, may not be appropriate for regions such as Asia, Latin America or Afr ... more

Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025

Lin, X.; Xu,Y.; Pan, X.; et al. Scientific reports (2020) CC2

Diabetes mellitus is a leading cause of mortality and reduced life expectancy. We aim to estimate the burden of diabetes by type, year, regions, and socioeconomic status in 195 countries and territories over the past 28 years, which provide information to achieve the goal of World Health Organizatio ... more

Questions and Answers on Covid-19 and Diabetes

World Health Organization WHO African Region (2020) C_WHO

Does Diabetes make someone vulnerable to getting COVID-19: People with Diabetes are not more likely to get the virus compared to the general public. However, if they contact CoVID-19, people with diabetes are more likely to have serious complications and become seriously ill from COVID-19, than t ... more

Pharmacological Primary Prevention of Diabetes Mellitus Type II: A Narrative Review

Naveed, A.; Farrukh, L.; Khawar Sana, M.; et al. National Library of Medicine (2020) CC2

The evolving epidemic of type 2 diabetes mellitus has challenged health-care professionals. It stands among the leading causes of mortality in the present world. It warrants new and versatile approaches to improve mortality and the associated huge quality-adjusted life years lost to it once diagnose ... more

Fact-sheet: If I have Diabetes, what do I need to know about COVID-19? Q and A on Covid-19 and NCDS

Pan American Health Organization PAHO; World Health Organization WHO (2020) C_WHO

ARE PEOPLE WITH DIABETES MORE LIKELY TO GET COVID-19? People with diabetes are more likely to become seriously ill from COVID-19, than those who do not have diabetes. Unfortunately, persons with diabetes who get COVID-19 are more likely to die than those without diabetes.

Si tengo diabetes, ¿qué debo saber acerca de la COVID-19? 21 de mayo del 2020

Pan American Health Organization PAHO; World Health Organization WHO (2020) C_WHO

ARE PEOPLE WITH DIABETES MORE LIKELY TO GET COVID-19? • People with diabetes are more likely to become seriously ill from COVID-19, than those who do not have diabetes. • Unfortunately, persons with diabetes who get COVID-19 are more likely to die than those without diabetes.

Se tenho diabetes, o que preciso saber sobre a COVID-19?

Pan American Health Organization PAHO; World Health Organization WHO (2020) C_WHO

Hearts - D: Diagnosis and Management of Type 2 Diabetes 2020

World Health Organization WHO; International Diabetes Federation (2020) C_WHO

Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabe ... more

Hearts - D: Диагностика и ведение сахарного диабета 2 типа

World Health Organization WHO; International Diabetes Federation (2020) C_WHO

WHO package of essential noncommunicable (PEN) disease interventions for primary health care

World Health Organization (WHO) World Health Organization (WHO) (2020) C_WHO

The "WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care" provides a set of cost-effective, evidence-based interventions to address noncommunicable diseases (NCDs) such as cardiovascular diseases, diabetes, chronic respiratory diseases, and cancers. Designed ... more

Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a Wo

Driscoll, A.J.; Hasan Arshad, S.; Bont, L. et al. Vaccine (2020) CC

The article reviews the impact of respiratory syncytial virus (RSV) on global health, emphasizing its significant burden on infants, children, and the elderly. It discusses current and emerging prevention strategies, including the development and implementation of vaccines and monoclonal antibodies. ... more

Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD)

Román-Rodríguez, M.; Tsiligianni, I.; Wiliams, S.; et al. International Primary Care - Respiratory Group (2020) CC2

The document "Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD)" from the IPCRG provides guidance on when to start, adjust, or discontinue ICS in COPD treatment. It highlights the benefits and risks, emphasizing personalized ... more

2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group

Cloutier, M. M.; Baptist, A.P.; Teach, S.J.; et al. The Journal of Allergy and Clinical Immunology (2020) CC2

The2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group was coordinated and supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Healt ... more